Tempest Therapeutics, Inc. (TPST)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 75/100 (HIGH), 5.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.6% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-21. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 1 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 16, 2026 · ingested Nov 16, 2026 |
| Insider activity | 1 | Current Updated within the last 10 days |
SEC EDGAR Form 4 Window ends: Nov 21, 2026 · ingested Nov 21, 2026 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 21, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 21, 2026 |
| Publications | 13 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 20, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 20.9/100 (grade F):
- Dilution risk: signal score 0.75, weight used 16%, 11.7 points
- Clinical trials: signal score 0.17, weight used 49%, 8.1 points
- Publications: signal score 0.65, weight used 1%, 0.6 points
- Short interest: signal score 0.10, weight used 6%, 0.6 points
- Insider buying (Form 4): signal score 0.00, weight used 29%, 0.0 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
- Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
- Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
- Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
- Tempest Therapeutics Announces Up to $7.5 Million Private Placement
- Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- MORC3 represses a tandem repeat enhancer to regulate interferon. — EMBO J 2026 Jul PMID 42249047
- Loss of Elp1 in cerebellar granule cell progenitors models ataxia phenotype of Familial Dysautonomia. — Neurobiol Dis 2024 Sep PMID 38996985
- First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. — Cancer Res Commun 2024 Apr 18 PMID 38551394
- The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. — Nat Commun 2024 Feb 24 PMID 38402224
- Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma. — Pancreas 2023 May 1 PMID 37782886
13 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Tempest Therapeutics, Inc..
Full TPST Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.